The introduction of Retatrutide ZPHC, at a dosage of 120mg, is sparking considerable buzz within the healthcare community. This novel dual GIP and GLP-1 receptor medication appears to provide notable improvements in body reduction compared to current therapies. Initial patient trials have demonstrated substantial decreases in body fat percentage, p